Business Wire

MAXON

10.4.2024 15:32:31 CEST | Business Wire | Press release

Share
Maxon One Spring 2024 Release Packs Particle Power, Toon Shading, and More

Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists, and creators of all types, today announced a game-changing update to Maxon One.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409558753/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Maxon One Spring 2024 release showcases groundbreaking updates to Cinema 4D, Redshift, Red Giant and more to enable users to bring stories to life with unparalleled creative freedom. Artist credit: Something's Awry

Motion designers, broadcasters, VFX artists, and more rely on Maxon One to promote products, frame shows, and realize clients’ visions. And, just in time for NAB, this spring release is packed with new creativity-boosting upgrades and tools, including Cinema 4D Particles, NPR rendering in Redshift, and Red Giant Geo.

Feature Highlights Include:

Cinema 4D 
Cinema 4D 2024.4 empowers 3D VFX artists and motion designers to create complex scenes with ease.

  • Design particle simulations intuitively with new Cinema 4D Particles! Integration with C4D’s Unified Simulation systems allows artists to control emission patterns, modify behaviors precisely, and orchestrate interactions with Maxon’s collection of simulation types, including Pyro, Cloth, soft bodies, and rigid bodies. Render particles scenes with Redshift, or cache and export them via Alembic. New Cinema 4D Particles presets are available in the Asset Browser, giving artists creative options for starting any project.

Redshift 
Redshift 3.6.0 features non-photorealistic rendering (NPR), more flexible Standard Volumes, support for AMD graphics, alpha mask support for Redshift area lights and more.

  • Render NPR line and toon looks in Redshift with new non-photoreal-render options, including a Contour node, a Toon Material node for cel shading, and a Tonemap Pattern shader for half-tone shading and other screen-space, grid-based shading styles.

Red Giant 
Red Giant 2024.2 features Red Giant Geo, a new tool that lets users texture, light, and clone 3D objects in After Effects. Rendering performance in Trapcode Particular has been improved significantly and there are new custom blur maps for Bokeh, as well as improvements to Looks’ UI.

Capsules 
Maxon One subscribers enjoy access to the expansive Maxon Capsules library, which includes a wide variety of assets to help kickstart any project. In addition to the library of Adobe Substance 3D materials Maxon released in partnership with Adobe recently, this release includes many great new additions such as Ivy Generator, Partition Modifier and Wood Floors Vol. 01.

Cineware 
Updates to Cineware for Unreal make it easier than ever to transfer materials between Cinema 4D to Unreal. Use Direct Link, and there’s no need to save files to disk when transferring. Note: Only works with Unreal Engine 5.0 and beyond and requires Cinema 4D 2023.0 or later versions.

More details at maxon.net. Assets are available to download here.

About Maxon 
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409558753/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye